{"brief_title": "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer", "brief_summary": "The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010", "condition": "Prostate Cancer", "intervention_type": "Drug", "intervention_name": "MDX-010 / MDX-010 + Docetaxel", "criteria": "Inclusion Criteria: - Clinical diagnosis of adenocarcinoma of the prostate. - Metastatic prostate cancer (positive bone scan or measurable disease). - Progressive disease after androgen deprivation. - No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer). Exclusion Criteria: - Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for greater than or equal to 5 years. - Previous occurrence of autoimmune disease. - Active infection requiring therapy including HIV or chronic hepatitis.", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00050596.xml"}